TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T2DM for at least 12 weeks prior to the Screening Visit~* Currently treated with a stable oral dose of metformin monotherapy for at least 12 weeks prior to the Screening Visit and until Day -3~* Have a glycosylated hemoglobin (HbA1c) value of between 6.5% and 10.0% at the Screening Visit~* Have a fasting plasma glucose (FPG) value of no more than 280 mg/dL at the Screening Visit and on Day -3~* Body Mass Index (BMI) of 25 to 40 kg/m2 (inclusive)~Exclusion Criteria:~* Known medical history or presence of Type 1 diabetes mellitus, Maturity Onset Diabetes of the Young or secondary forms of diabetes~* Known medical history or presence of diabetic complications~* Have taken anti-diabetic medications (other than metformin) or medications that act mainly in the gastrointestinal tract (e.g., orlistat, acarbose) within 12 weeks prior to the Screening Visit or from the Screening Visit to Day -3~* Have uncontrolled hypertension (systolic blood pressure of at least 160 mmHg or diastolic blood pressure of at least 95 mmHg) at the Screening Visit~* Have impaired renal function (estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- JTT-662 5 mg (Type: EXPERIMENTAL): JTT-662 5 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
- JTT-662 10 mg (Type: EXPERIMENTAL): JTT-662 10 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
- JTT-662 20 mg (Type: EXPERIMENTAL): JTT-662 20 mg orally once daily from Day 1 to Day 28, after a single dose of placebo on Day -1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo orally once daily from Day -1 to Day 28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Type 2 diabetes mellitus~* On a stable dose of metformin (≥1500 mg/day) for at least 12 weeks with inadequate glycemic control~* Females of reproductive potential agree to remain abstinent or use or have their partner use acceptable methods of birth control~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* Treated with any antihyperglycemic agents (AHA) therapies other than the protocol-required metformin within the prior 12 weeks of study participation or with omarigliptin at any time prior to signing informed consent~* On a weight loss program and is not in the maintenance phase or has~started a weight loss medication in the past 6 months or has undergone bariatric surgery within 12 months prior to study participation~* Medical history of active liver disease (other than non-alcoholic~hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease~* Human immunodeficiency virus~* New or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke or transient ischemic neurological disorder within the past 3 months~* History of malignancy ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer, or in situ~cervical cancer~* Clinically important hematological disorder (such as aplastic anemia,~myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* Pregnant or breast-feeding, or is expecting to conceive or donate eggs~during the trial, including 21 days following the last dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omarigliptin (Type: EXPERIMENTAL): Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
- Glimepiride (Type: ACTIVE_COMPARATOR): Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Fractional Exhaled Nitric Oxide in the Identification of Non-adherence in Difficult Asthma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Phase 1 Inclusion Criteria:~* Subjects with difficult to control asthma~* FeNO \> 45 ppb at a flow rate of 50 ml/sec on 2 sequential occasions at clinical review~* Non-adherent group: \< 50% prescription filling of inhaled corticosteroid therapy in the previous 6 months~* Adherent group: \> 75% prescription filling of inhaled corticosteroid therapy in the previous 6 months~Phase 1 Exclusion Criteria:~* Current smoker~* Pregnancy~* Other significant respiratory disease~Phase 2 Inclusion Criteria:~* Subjects with difficult to control asthma~* FeNO \> 45 ppb at a flow rate of 50 ml/sec on 2 sequential occasions at clinical review~Phase 2 Exclusion Criteria:~* Current smoker~* Pregnancy~* Other significant respiratory disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-adherent (Type: OTHER): None
- Adherent (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Assessment of ALD403 in Chronic Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year~* During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days were assessed as migraine days with at least 5 migraine attacks as recorded in the eDiary~* Headache eDiary was completed on at least 22 of the 28 days prior to randomization~Exclusion Criteria:~* Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional pain syndrome) or any pain syndrome that requires regular analgesia~* Psychiatric conditions that are uncontrolled and untreated, including conditions that are not controlled for a minimum of 6 months prior to screening.~* History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, migraine with brainstem aura, sporadic and familial hemiplegic migraine~* Unable to differentiate migraine from other headaches~* Subject has received botulinum toxin for migraine or for any other medical/cosmetic reasons requiring injections in the head, face, or neck within 4 months prior to screening.~* Have any clinically significant concurrent medical condition~* Receipt of any monoclonal antibody treatment within 6 months of screening (within or outside a clinical trial)~* Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ALD403 Dose Level 1 (Type: EXPERIMENTAL): ALD403 Dose Level 1 (IV)
- ALD403 Dose Level 2 (Type: EXPERIMENTAL): ALD403 Dose Level 2 (IV)
- ALD403 Dose Level 3 (Type: EXPERIMENTAL): ALD403 Dose Level 3 (IV)
- ALD403 Dose Level 4 (Type: EXPERIMENTAL): ALD403 Dose Level 4 (IV)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (IV)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 18 year old undergoing transcatheter ASD closure with the Amplatzer Septal Occluder device (AGA medical Corp., MN, USA).~* Female subjects must be post-menopausal, surgically sterile, or using an effective method of birth control.~* Signed an informed consent document.~Exclusion Criteria:~* Allergy or intolerance to any of the antithrombotic drugs (aspirin, clopidogrel) used in the study.~* Need for anticoagulation therapy.~* Use of ASD closure devices other than the Amplatzer Septal Occluder device.~* History of migraine headaches (based on migraine headache questionnaire).~* Refusal to sign the informed consent.~* Pregnancy or breast-feeding or planning to become pregnant during the study.~* Previous stroke.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin + clopidogrel (Type: EXPERIMENTAL): Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
- Aspirin (Type: ACTIVE_COMPARATOR): Aspirin (80 mg/day) for 3 months following ASD closure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females, 18 years old, with type 2 diabetes and with inadequate glycemic control~* Drug naive or treated with anti-diabetic medication for \< 24 weeks~* C-peptide ≥ 1.0 ng/mL~* Body Mass Index ≤ 45.0 kg/m²~Exclusion Criteria:~* AST and/or ALT \> 3 times ULN~* Serum total bilirubin \> 2 mg/dL~* Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women~* Creatine kinase ≥ 3 times ULN~* Symptoms of severely uncontrolled diabetes~* Currently unstable or serious cardiovascular, renal, hepatic, hematological, oncological, endocrine, psychiatric, or rheumatic diseases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): None
- Group 2 (Type: EXPERIMENTAL): None
- Group 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Must be of Taiwanese or Korean ancestry living in Taiwan or South Korea, respectively~* Have a diagnosis of plaque-type psoriasis at least 6 months prior to first administration of study agent (patients with concurrent psoriatic arthritis may be enrolled)~* Have plaque-type psoriasis covering at least 10% of total body surface area at screening and at the time of first study agent administration~* PASI score of 12 or greater at the time of screening and at time of first study agent administration~* Candidate of phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment)~* Be able to adhere to the study visit schedule and other protocol requirements~* Capable of giving informed consent prior to any study related procedures.~Exclusion Criteria:~* Currently have a non-plaque form of psoriasis~* Have current drug-induced psoriasis~* Are pregnant or nursing or planning pregnancy (both men and women) while enrolled in the study~* Have used any investigational drug within the previous 4 weeks or 5 times the half life of the investigational agent, whichever is longer~* Have used any biologic within the previous 3 months or 5 times the half life of the biologic, whichever is longer~* Have been hospitalized in the past 3 years for asthma, ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or required more than one short-term course of oral corticosteroids for asthma within the previous year~* Have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis prior to screening.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo - Controlled Period (CP) (Type: PLACEBO_COMPARATOR): None
- Ustekinumab 45 mg - CP (Type: EXPERIMENTAL): None
- Placebo to ustekinumab 45 mg - after CP (Type: EXPERIMENTAL): None
- Ustekinumab 45 mg - after CP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pertubation With Lignocaine in Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 20 years~* endometriosis verified by laparoscopy~* dysmenorrhea or pelvic pain defined as a pain-score of \>50 mm (VAS)~* normal Fallopian tubes~* regular menstrual cycles 21-35 days~* treatment with oral contraceptives (OC) ongoing \> 1 month and continued during the trial~* previous hormonal treatment discontinued \> 1 month (OC, gestagens) and \> 6 months (GnRH)~* no wish for pregnancy during the study~* normal Pap-smear~* negative Chlamydia-test~* negative pregnancy-test~* informed consent given and signed~Exclusion Criteria:~* Continuous treatment with medication that may increase risk for infection - clinical signs of pelvic inflammatory disease~* hyperreactivity to local anesthesia~* fibroids \> 2 cm~* ongoing treatment with GnRH-analog~* ongoing continuous treatment with high dose gestagens~* pregnancy~* peritubal adhesions~* occluded Fallopian tubes~* inability to understand information or comply with the study procedures~* participation in a clinical study within one year before the present study~* any disease or laboratory finding considered of importance by the investigator not to include the patient

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pertubation with Endole® (lignocaine) (Type: EXPERIMENTAL): Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
- Placebo (Type: PLACEBO_COMPARATOR): Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy according to the AGA criteria, with no clinically significant findings~* Patient has successfully completed protocol procedures (with no clinically significant findings): physical exam, 12-lead ECG, or clinical laboratory tests~* Patient meets protocol criteria for CC: reports \< 3 bowel movements per week and reports straining, lumpy or hard stools, and/or sensation of incomplete evacuation during \> 25% of BMs~* Patient demonstrates continued chronic constipation through Pretreatment Period~* Patient is compliant with IVRS~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with Irritable Bowel Syndrome (IBS)~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Linaclotide 290 micrograms
- 2 (Type: EXPERIMENTAL): Linaclotide 145 micrograms
- 3 (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary pterygium with moderate vascularity (Pterygium Hyperemia Grading Scale ≥ 3)~Exclusion Criteria:~* Active ocular disease, corneal abnormalities other than pterygium, active ocular infection, or any ocular pathology unrelated to pterygium in either eye that could affect the assessment of the pterygium~* History of ocular herpes disease in either eye~* Any ocular surgical procedure within the last 3 months~* Female patients who are pregnant, nursing, or planning a pregnancy during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CBT-001 Ophthalmic Solution Single dose (Type: EXPERIMENTAL): One drop in the study administered one time only for one day
- Vehicle (Type: PLACEBO_COMPARATOR): One drop in the study administered three times daily (TID) for 4 weeks
- CBT-001 Ophthalmic Solution Multidose (Type: EXPERIMENTAL): One drop in the study administered three times daily (TID) for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant female adult ≥18 years of age at time of enrollment.~2. has laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay (result of the PCR is not necessary for inclusion, but has to approved latest within 48-72 hours after registration)~3. Willingness of men and women of childbearing potential to use highly effective contraceptive methods by abstinence or by using at least two contraceptive methods from the date of consent to the end of the study~4. severe lung disease as defined by following:~   1. Recent intubation~  2. Requirement of invasive ventilation moderate to severe pulmonary oxygen exchange disturbance as defined by (PaO2/FiO2) ≤ 200 mmHg at a PEEP ≥ 5mm H2O~  3. Serum LDH \> 283 U/l~  4. Ferritin above normal value~  5. CT-scan: pulmonary infiltration compatible with Covid-19 disease~5. Patient or patient´s representative must provide written informed consent (and assent if applicable) before any study assessment is performed.~Exclusion Criteria:~1. Uncontrolled HIV infection~2. Active tuberculosis (result of positive tuberculosis infection is not necessary for exclusion, but has to approved later on during patient´s intervention)~3. Chronic kidney disease requiring dialysis~4. ALT/AST \> 5 times the upper limit of normal.~5. Pregnancy or breast feeding.~6. Allergy to study medication~7. Simultaneous participation in another clinical trial with an experimental treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib treatment (Type: EXPERIMENTAL): Ruxolitinib will be administered p.o. or by gavage feeding for max 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \<18 years~* myeloablative conditioning and autologous or allogeneic stem cell transplantation with at least one of the following risk factors for VOD:~  1. Pre-existing liver disease~ 2. Second myeloablative HSCT~ 3. History of treatment with gemtuzumab ozogamicin (MYLOTARGÒ, GO, CMA-676, Wyeth)~ 4. Allogeneic HSCT for leukemia beyond the second relapse~ 5. Osteopetrosis (OP)~ 6. Conditioning with busulfan and melphalan~ 7. Macrophage activating syndromes (MAS, like hemophagocytic lymphohistiocytosis, Griscelli, Chediak-Higashi~ 8. Adrenoleukodystrophy (ALD)~Exclusion Criteria:~* Pregnant patients~* Patients who are transplanted but do not fulfill any of the above mentioned criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis Arm (Type: EXPERIMENTAL): None
- Control Arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete